Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 3
1993 2
1994 1
1995 5
1997 1
1998 1
2000 4
2001 2
2002 4
2003 6
2004 2
2005 3
2006 1
2007 2
2008 3
2009 2
2011 1
2012 2
2013 3
2015 1
2016 3
2017 2
2019 2
2020 2
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

61 results
Results by year
Filters applied: . Clear all
Page 1
CRISPR-engineered T cells in patients with refractory cancer.
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH. Stadtmauer EA, et al. Among authors: carreno bm. Science. 2020 Feb 28;367(6481):eaba7365. doi: 10.1126/science.aba7365. Epub 2020 Feb 6. Science. 2020. PMID: 32029687 Clinical Trial.
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
Linette GP, Carreno BM. Linette GP, et al. Among authors: carreno bm. Curr Hematol Malig Rep. 2019 Aug;14(4):286-291. doi: 10.1007/s11899-019-00523-x. Curr Hematol Malig Rep. 2019. PMID: 31187421 Free PMC article. Review.
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. Latchman Y, et al. Among authors: carreno bm. Nat Immunol. 2001 Mar;2(3):261-8. doi: 10.1038/85330. Nat Immunol. 2001. PMID: 11224527
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.
Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, Baroja ML, McCuaig S, Costeas C, Gabunia K, Scholler J, Posey AD Jr, O'Hara MH, Smole A, Powell DJ Jr, Garcia BA, Vonderheide RH, Linette GP, Carreno BM. Bear AS, et al. Among authors: carreno bm. Nat Commun. 2021 Jul 16;12(1):4365. doi: 10.1038/s41467-021-24562-2. Nat Commun. 2021. PMID: 34272369 Free PMC article.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. Freeman GJ, et al. Among authors: carreno bm. J Exp Med. 2000 Oct 2;192(7):1027-34. doi: 10.1084/jem.192.7.1027. J Exp Med. 2000. PMID: 11015443 Free PMC article.
Heating up cancer vaccines.
Ghassemi S, Carreno BM. Ghassemi S, et al. Among authors: carreno bm. Sci Immunol. 2017 Nov 10;2(17):eaap9419. doi: 10.1126/sciimmunol.aap9419. Sci Immunol. 2017. PMID: 29127107
A Vaccine for Cancer?
Carreno BM, Mardis ER. Carreno BM, et al. Sci Am. 2016 Apr;314(4):46. doi: 10.1038/scientificamerican0416-46. Sci Am. 2016. PMID: 27082191 No abstract available.
The B7 family of immune-regulatory ligands.
Collins M, Ling V, Carreno BM. Collins M, et al. Among authors: carreno bm. Genome Biol. 2005;6(6):223. doi: 10.1186/gb-2005-6-6-223. Epub 2005 May 31. Genome Biol. 2005. PMID: 15960813 Free PMC article. Review.
Neoantigen Vaccines Pass the Immunogenicity Test.
Linette GP, Carreno BM. Linette GP, et al. Among authors: carreno bm. Trends Mol Med. 2017 Oct;23(10):869-871. doi: 10.1016/j.molmed.2017.08.007. Epub 2017 Aug 31. Trends Mol Med. 2017. PMID: 28867556 Free PMC article.
61 results